Page last updated: 2024-10-24

negative regulation of retinoic acid receptor signaling pathway

Definition

Target type: biologicalprocess

Any process that stops, prevents, or reduces the frequency, rate or extent of retinoic acid receptor signaling pathway activity. [GOC:dgh]

Negative regulation of retinoic acid receptor signaling pathway involves a complex interplay of molecular mechanisms that attenuate the activity of retinoic acid receptors (RARs), nuclear receptors responsible for mediating the effects of retinoic acid (RA). RA, a vitamin A derivative, plays a critical role in various developmental processes, including embryonic development, cell differentiation, and immune regulation. The signaling pathway is initiated by the binding of RA to RARs, which form heterodimers with retinoid X receptors (RXRs). These heterodimers bind to specific DNA sequences called retinoic acid response elements (RAREs) located in the promoter regions of target genes, leading to the regulation of gene expression. Negative regulation of this pathway is essential to prevent excessive activation and maintain homeostasis.

**Mechanisms of Negative Regulation:**

1. **Ligand Availability:**
* **RA synthesis and degradation:** The production and breakdown of RA are tightly controlled. Enzymes like retinaldehyde dehydrogenase (RALDH) are responsible for synthesizing RA, while cytochrome P450 enzymes like CYP26A1 and CYP26B1 catalyze RA degradation, limiting its availability.
* **RA sequestration:** Cellular proteins like cellular retinoic acid-binding protein (CRABP) bind to RA, reducing its availability for RARs.

2. **RAR expression and activity:**
* **RAR gene transcription:** The expression levels of RAR genes can be regulated by various factors, including other signaling pathways.
* **RAR phosphorylation:** Phosphorylation of RARs by kinases like protein kinase A (PKA) and protein kinase C (PKC) can modulate their activity and target gene selectivity.
* **RAR degradation:** Proteasomal degradation of RARs can reduce their levels in the cell.

3. **Corepressor Recruitment:**
* **Nuclear receptor corepressors (NCoRs):** In the absence of RA, RARs recruit NCoRs like NCoR1 and SMRT to the RAREs, leading to the repression of target gene transcription. NCoRs can act by recruiting histone deacetylases (HDACs), which remove acetyl groups from histones, causing chromatin condensation and silencing gene expression.

4. **Antagonist binding:**
* **RA antagonists:** Some compounds, like synthetic retinoic acid receptor antagonists, can bind to RARs and block the binding of RA, effectively inhibiting the signaling pathway.

5. **MicroRNAs (miRNAs):**
* **miRNA-mediated regulation:** Specific miRNAs can target RAR transcripts or downstream signaling proteins, regulating their expression and activity.

**Consequences of Negative Regulation:**

Negative regulation of RA signaling is crucial for:

* **Maintaining homeostasis:** Preventing excessive RA signaling, which could lead to developmental abnormalities and other pathological conditions.
* **Fine-tuning tissue-specific responses:** Ensuring appropriate levels of gene expression in different tissues and at different developmental stages.
* **Adaptive responses:** Allowing cells to adjust their responses to changing levels of RA or other environmental cues.

**Dysregulation and Disease:**

Disruption of the negative regulation of RA signaling can contribute to various diseases, including:

* **Cancer:** In some cancers, the expression of negative regulators of RA signaling is dysregulated, leading to aberrant RA signaling and tumor growth.
* **Developmental disorders:** Defects in RA signaling pathways can lead to birth defects and other developmental abnormalities.
* **Immune system disorders:** RA signaling plays a role in immune regulation, and dysregulation of this pathway can contribute to autoimmune diseases.

**Overall, negative regulation of RA signaling is a complex process involving multiple layers of molecular control. These mechanisms ensure that RA signaling is tightly regulated and functions appropriately in diverse physiological contexts. Disruptions in this pathway can have significant consequences for development and health.**"

Proteins (3)

ProteinDefinitionTaxonomy
Cytochrome P450 26B1A cytochrome P450 26B1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9NR63]Homo sapiens (human)
Histone-lysine N-methyltransferase EZH2A histone-lysine N-methyltransferase EZH2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15910]Homo sapiens (human)
Cytochrome P450 26A1A cytochrome P450 26A1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O43174]Homo sapiens (human)

Compounds (15)

CompoundDefinitionClassesRoles
ketoconazole1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
liarozoleliarozole: inhibits all-trans-retinoic acid 4-hydroxylase; effective against hormone-dependent and hormone-independent tumors; R 75251 is chlorohydrate of R 61405; a potent inhibitor of retinoic acid metabolism; USAN name - liarozole fumaratebenzimidazoles
3-deazaneplanocin3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist
bexarotenebenzoic acids;
naphthalenes;
retinoid
antineoplastic agent
tanshinonetanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agentabietane diterpenoidanticoronaviral agent
przewaquinone dprzewaquinone D: isolated from root of Salvia przewalskii; structure given in first source; RN given refers to the trans- isomer, przewaquinone D
sr 11237SR 11237: structure given in first source
tanshinone ii atashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first sourceabietane diterpenoid
s-adenosylhomocysteineS-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine.

S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions.
adenosines;
amino acid zwitterion;
homocysteine derivative;
homocysteines;
organic sulfide
cofactor;
EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor;
EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor;
epitope;
fundamental metabolite
r 115866N-{4-[2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothiazol-2-amine : A member of the class of benzothiazoles that is 2-amino-1,3-benzothiazole in which one of the amino hydrogens is replaced by a 4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl group.

R 115866: structure in first source

talarozole : A racemate comprising equimolar amounts of (R)- and (S)-talarozole. It is used for the treatment of keratinization disorders, psoriasis and acne.
aromatic amine;
benzothiazoles;
secondary amino compound;
triazoles
epz005687EPZ005687: inhibits EZH2 protein; structure in first sourceindazoles
epz-6438tazemetostat: a histone methyltransferase EZH2 inhibitor with antineoplastic activity
gsk-2816126GSK-2816126: inhibits EZH2 methyltransferase; structure in first sourcepiperazines;
pyridines
gsk343GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).

GSK343: an EZH2 methyltransferase inhibitor
aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
1-[(1R)-1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide(R)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide: EZH2 inhibitorindolecarboxamide